Literature DB >> 11094043

Physiological induction of a beta-adrenergic receptor kinase inhibitor transgene preserves ss-adrenergic responsiveness in pressure-overload cardiac hypertrophy.

B S Manning1, K Shotwell, L Mao, H A Rockman, W J Koch.   

Abstract

BACKGROUND: Transgenic mice with constitutive myocardium-targeted expression of a peptide inhibitor of the ss-adrenergic receptor kinase (ssARKct) have increased in vivo cardiac function and enhanced ss-adrenergic receptor (ssAR) responsiveness. METHODS AND
RESULTS: In the present study, we created transgenic mice with myocardium-targeted ssARKct transgene expression under control of the CARP (cardiac ankyrin repeat protein) promoter, which is active during cardiac development and inactive in the normal adult mouse heart. Consistent with this, adult CARP-ssARKct transgenic mice have normal in vivo cardiac contractility and ssAR responsiveness indistinguishable from their nontransgenic littermates (NLCs). However, because CARP is in a group of fetal genes activated in the adult ventricle during hypertrophy, we subjected animals to transverse aortic constriction (TAC) to induce pressure overload. Seven days after TAC, CARP-ssARKct hearts had elevations in left ventricular mass similar to those in NLCs; however, TAC did induce demonstrable ssARKct expression in the transgenic hearts. TAC in NLC mice resulted in an upregulation of myocardial ssARK1 and a loss of ssAR-mediated inotropic reserve. Importantly, although ssARK1 was increased in the hypertrophic CARP-ssARKct mice, the in vivo loss of ssAR responsiveness was not seen after induced ssARKct expression.
CONCLUSIONS: These results demonstrate that acute ssARK1 inhibition can restore lost myocardial ssAR responsiveness and inotropic reserve in vivo. Furthermore, these mice demonstrate the novel utility of the CARP promoter as an inducible element responsive to pathophysiological conditions in the adult heart.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11094043     DOI: 10.1161/01.cir.102.22.2751

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  5 in total

Review 1.  GRK mythology: G-protein receptor kinases in cardiovascular disease.

Authors:  Gerald W Dorn
Journal:  J Mol Med (Berl)       Date:  2009-02-20       Impact factor: 4.599

2.  Impaired β-adrenergic responsiveness accentuates dysfunctional excitation-contraction coupling in an ovine model of tachypacing-induced heart failure.

Authors:  Sarah J Briston; Jessica L Caldwell; Margaux A Horn; Jessica D Clarke; Mark A Richards; David J Greensmith; Helen K Graham; Mark C S Hall; David A Eisner; Katharine M Dibb; Andrew W Trafford
Journal:  J Physiol       Date:  2011-01-17       Impact factor: 5.182

3.  A beta-blocker, propranolol, decreases the efficacy from enzyme replacement therapy in Pompe disease.

Authors:  Sang-Oh Han; Rand Pope; Songtao Li; Priya S Kishnani; Richard Steet; Dwight D Koeberl
Journal:  Mol Genet Metab       Date:  2015-10-03       Impact factor: 4.797

Review 4.  GRK2 in the heart: a GPCR kinase and beyond.

Authors:  Zheng Maggie Huang; Erhe Gao; J Kurt Chuprun; Walter J Koch
Journal:  Antioxid Redox Signal       Date:  2014-05-13       Impact factor: 8.401

Review 5.  G protein-coupled receptor kinases in normal and failing myocardium.

Authors:  Zheng Maggie Huang; Jessica I Gold; Walter J Koch
Journal:  Front Biosci (Landmark Ed)       Date:  2011-06-01
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.